DNLI News and Press, Denali Therapeutics Inc. From 11/28/25

2025-11-28 13:30:48 ET More on the markets Is There Something Wrong With This Rally? No, And These 7 Graphs Prove It What To Expect In December There's A Bigger Threat To Markets Unfolding Now, And It's Not AI Infrastructure Trump to halt migration from all '...

2025-11-22 03:03:24 ET Denali Therapeutics Inc. (DNLI) Jefferies London Healthcare Conference 2025 November 18, 2025 7:30 AM EST... Read the full article on Seeking Alpha For further details see: Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Confere...

2025-11-06 17:28:14 ET More on Denali Therapeutics Denali Therapeutics Inc. (DNLI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript Denali Therapeutics gets FDA review extension for tividenofusp alfa Goldman's 48 potential M&A candid...

Tividenofusp alfa BLA review process for accelerated approval for MPS II continues with productive engagement with the FDA; commercial launch preparations on track DNL126 Phase 1/2 study enrollment completed, supporting an accelerated approval path in MPS IIIA Two new regulatory applicati...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren has been appointed to Denali’s Board of Directors. Mr. Van Hauwermeiren is co-fou...

Curaleaf Holdings Inc (CURLF) is expected to report $-0.07 for Q3 2025 Southwest Gas Holdings Inc. (DE) (SWX) is expected to report $0.09 for Q3 2025 Terreno Realty Corporation (TRNO) is expected to report $0.65 for Q3 2025 Bio-Techne Corp (TECH) is expected to report $0.36 for Q1 202...

2025-10-13 16:31:56 ET More on Denali Therapeutics Denali Therapeutics Inc. (DNLI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript Goldman's 48 potential M&A candidates Seeking Alpha’s Quant Rating on Denali Therapeutics ...

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline of the Biologics License Application (BLA) seeking accelerated approval of tividenofusp alfa for...

2025-09-28 15:14:50 ET More on M&A Electronic Arts: Sell The Takeover News Molson Coors: It's Reasonably Valued Now, But Weak Growth Prospects May Not Support An Upside Yet Occidental in talks to sell petrochemical business for $10 billion: FT Jared Kushn...

2025-09-15 20:21:09 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F stock portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 08/14/2025. The 13F portfolio value in...